Zentalis Pharmaceuticals, Inc.
1.5300-0.18 (-10.5%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · ZNTL · USD
Key Stats
Market Cap
110.37MP/E (TTM)
-Basic EPS (TTM)
-2.28Dividend Yield
0%Recent Filings
8-K
CLO transition at Zentalis
Zentalis Pharmaceuticals announced on August 26, 2025, that Chief Legal Officer Andrea Paul will resign effective September 18 to join a major law firm, remaining as a non-executive employee until October 1 with a release agreement providing her 2025 bonus and continued equity vesting. The company swiftly appointed James B. Bucher, a veteran life sciences executive with over 30 years of experience in transactions and governance, to the role starting the same date. Bucher's expertise in mergers and capital raises bolsters Zentalis as it advances azenosertib into registration trials. Leadership transitions carry risks to continuity.
10-Q
Q2 FY2025 results
Zentalis Pharmaceuticals narrowed its focus on azenosertib in Q2 FY2025 ended June 30, 2025, posting a net loss of $26.9M, improved from $88.3M y/y, while YTD net loss widened to $75.2M from $78.2M y/y amid restructuring costs. Operating expenses dropped sharply to $36.1M q/q and $81.7M YTD (derived), driven by 43% lower R&D on azenosertib external costs and halved G&A, yet a $7.8M one-time restructuring charge hit YTD results. Cash burn eased to $67.3M YTD from $87.1M y/y, with $303.4M in cash and equivalents funding operations into late 2027; no debt, but Immunome equity securities swung to a $4.6M YTD loss. DENALI Part 2a dosing began, eyeing topline data by 2026 end. Clinical trials may falter without biomarker validation.
8-K
Zentalis Q2 loss shrinks, cash extends
Zentalis Pharmaceuticals reported Q2 2025 net loss of $26.9 million, down sharply from $88.3 million last year, thanks to slashed R&D expenses at $27.6 million and G&A at $8.4 million after January's restructuring. Cash stands at $303.4 million, funding operations into late 2027—past DENALI Phase 2 topline data expected year-end 2026. Restructuring done. Trial on track for potential accelerated approval in Cyclin E1-positive PROC.
8-K
Zentalis annual meeting results
Zentalis Pharmaceuticals held its 2025 Annual Meeting on June 17, with 80.9% of shares represented. Scott Myers won election as Class II director with strong support, while Karan Takhar and Luke Walker, M.D., faced significant withheld votes yet secured seats. Ernst & Young LLP's appointment as auditors passed overwhelmingly, but executive pay approval split investors nearly evenly. Board continuity holds firm.
8-K
ASCO Phase 1 trial results
Zentalis Pharmaceuticals unveiled Phase 1 dose-escalation results for azenosertib combined with encorafenib and cetuximab in BRAFV600E mutant metastatic colorectal cancer patients at the 2025 ASCO meeting on May 31. The regimen showed a manageable safety profile at the MTD of azenosertib 300 mg, encorafenib 75 mg, and cetuximab 500 mg/m², with asthenia (36%) and decreased appetite (34%) as top TRAEs; no DLTs occurred there. Among 41 efficacy-evaluable patients, responses included 2 CRs, 6 PRs, and 13 SDs. Early signals suggest antitumor activity, but PD drove most discontinuations.
ARTL
Artelo Biosciences, Inc.
3.53+0.17
ATOS
Atossa Therapeutics, Inc.
0.88-0.06
ENTO
Entero Therapeutics Inc.
4.46+0.51
LSTA
Lisata Therapeutics, Inc.
2.66-0.12
NUVL
Nuvalent, Inc.
102.97+1.75
NVCT
Nuvectis Pharma, Inc.
6.77+0.34
OTLC
Oncotelic Therapeutics, Inc.
0.10+0.00
PTHS
Pelthos Therapeutics Inc.
32.50+0.05
ZBIO
Zenas BioPharma, Inc.
28.01-2.18
ZLAB
Zai Lab Limited
25.32-0.09